SEARCH

SEARCH BY CITATION

References

  • Antony T., Hoyer W., Cherny D., Heim G., Jovin T. M. and Subramaniam V. (2003) Cellular polyamines promote the aggregation of α-synuclein. J. Biol. Chem. 0, 32353240.
  • Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A. and And. Struhl K. (1997) Current Protocols in Molecular Biology. John Wiley & Sons, New York.
  • Baba M., Nakajo S., Tu P.-H., Tomita T., Nakaya K., Lee V. M.-Y., Trojanowski J. Q. and Iwatsubo T. (1998) Aggregation of α-synuclein in Lewy bodies. Am. J. Pathol. 152, 879884.
  • Baumeister R. and Ge L. (2002) The worm in us –Caenorhabditis as a model of human disease. Trends Biotechnol. 20, 147148.
  • Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 13461349.
  • Crittenden S. L. and Kimble J. (1999) Confocal methods for Caenorhabditis elegans. Methods Mol. Biol. 122, 141151.
  • Culetto E. and Sattelle D. B. (2000) A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet. 9, 869877.
  • Duerr J. S., Frisby D. L., Gaskin J., Duke A., Asermely K., Huddleston D., Eiden L. E. and Rand J. B. (1999) The cat-1 gene of Caenorhabditis elegans encodes a vesicular monoamine transporter required for specific monoamine-dependent behaviors. J. Neurosci. 19, 7284.
  • Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394398.
  • Forno L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259272.
  • Graham R. W., Jones D. and Candido E. P. (1989) UbiA, the major polyubiquitin locus in Caenorhabditis elegans, has unusual structural features and is constitutively expressed. Mol. Cell. Biol. 9, 268277.
  • Hallam S., Singer E., Waring D. and Jin Y. (2000) The C. elegans NeuroD homolog cnd-1 functions in multiple aspects of motor neuron fate specification. Development 127, 42394252.
  • Hsu L. J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M. and Masliah E. (2000) Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401410.
  • Iwasaki K., Staunton J., Saifee O., Nonet M. and Thomas J. H. (1997) aex-3 encodes a novel regulator of presynaptic activity in C. elegans. Neuron 18, 613622.
  • Jin Y., Hoskins R. and Horvitz H. R. (1994) Control of type-D GABAergic neuron differentiation by C. elegans UNC-30 homeodomain protein. Nature 372, 780783.
  • Jorgensen E. M. and Mango S. (2002) The art and design of genetic screens: Caenorhabditis elegans. Nat. Genet. 3, 356369.
  • Junn E., Ronchetti R. D., Quezado M. M., Kim S.-Y. and Mouradian M. M. (2003) Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 100, 20472052.
  • Kahle P. J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., Van Der Putten H., Probst A., Kremmer E., Kretzschmar H. A. and Haass C. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 63656373.
  • Kahle P. J., Haass C., Kretzschmar H. A. and Neumann M. (2002) Structure/function of α-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J. Neurochem. 82, 449457.
  • Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. and Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 27802791.
  • Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106108.
  • Lansbury P. T. and Brice A. (2002) Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12, 299306.
  • Lee F. J. S., Liu F., Pristupa Z. B. and Niznik H. B. (2001) Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916926.
  • Lee M. K., Stirling W., Xu Y., Xu X., Qui D., Mandir A. S., Dawson T. M., Copeland N. G., Jenkins N. A. and Price D. L. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53[RIGHTWARDS ARROW]Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 89688973.
  • Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M. J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P. J., Wilkinson K. D. and Polymeropoulos M. H. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451452.
  • Link C. D. (2001) Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech. Ageing Dev. 122, 16391649.
  • Liu Y., Fallon L., Lashuel H. A., Liu Z. and Lansbury P. T. Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209218.
  • Lucking C. B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B. S., Meco G., Denefle P., Wood N. W., Agid Y. and Brice A. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342, 15601567.
  • Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 12651268.
  • McLean P. J., Kawamata H., Shariff S., Hewett J., Sharma N., Ueda K., Breakefield X. O. and Hyman B. T. (2002) TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J. Neurochem. 83, 846854.
  • Mello C. and Fire A. (1995) DNA transformation. Methods Cell Biol. 48, 451482.
  • Miller K. G., Alfonso A., Nguyen M., Crowell J. A., Johnson C. D. and Rand J. B. (1996) A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Proc. Natl Acad. Sci. USA 93, 1259312598.
  • Nass R. and Blakely R. D. (2003) The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 43, 521544.
  • Nass R., Miller D. M. and Blakely R. D. (2001) C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat. Disord. 7, 185191.
  • Nass R., Hall D. H., Miller D. M. III and Blakely R. D. (2002) Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 99, 32643269.
  • Negro A., Brunati A. M., Conella-Deana A., Massimino M. L. and Pinna L. A. (2002) Multiple phosphylation of α-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16, 210212.
  • Olanow C. W. and Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123144.
  • Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J. and Wolozin B. (1999) Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 57825791.
  • Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I. and Nussbaum R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 20452047.
  • Van Der Putten H., Wiederhold K. H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W. P., Ruegg M. A., Lin S., Caroni P., Sommer B., Tolnay M. and Bilbe G. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 60216029.
  • Richfield E. K., Thiruchelvam M. J., Cory-Slechta D. A., Wuertzer C., Gainetdinov R. R., Caron M. G., Di Monte D. A. and Federoff H. J. (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175, 3548.
  • Sawin E. R. (1996) Genetic and cellular analysis of modulated behaviors. Caenorhabditis Elegans. PhD Thesis, Massachusetts Institute of Technology.
  • Seo J. H., Rah J. C., Choi S. H., Shin J. K., Min K., Kim H. S., Park C. H., Kim S., Kim E. M., Lee S. H., Lee S., Suh S. W. and Suh Y. H. (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16, 18261828.
  • Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. and Selkoe D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263269.
  • Sommer B., Barbieri S., Hofele K., Wiederhold K., Probst A., Mistl C., Danner S., Kauffmann S., Spooren W., Tolnay M., Bilbe G., Van Der Putten H., Kafmann S., Caromi P. and Ruegg M. A. (2000) Mouse models of alpha-synucleinopathy and Lewy pathology. Exp. Gerontol. 35, 13891403.
  • Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-Synuclein in Lewy bodies. Nature 388, 839840.
  • Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L. and Goedert M. (1998) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205208.
  • Sulston J., Dew M. and Brenner S. (1975) Dopaminergic neurons in the nematode C. elegans. J. Comp. Neurol. 163, 215226.
  • Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L. and Masliah E. (1998) Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders Am. J. Pathol. 152, 367372.
  • Thomas J. H. and Lockery S. (1999) Neurobiology, in C. Elegans: a Practical. Approach (HopeI., ed.), pp. 143176. Oxford University Press, Oxford.
  • Uversky V. N., Cooper E. M., Bower K. S. and Fink A. L. (2001) Accelerated α-synuclein fibrillation in crowed milieu. FEBS Lett. 515, 99103.
  • Wang W. and Shakes D. C. (1997) Expression patterns and transcript processing of ftt-1 and ftt-2, two C. elegans 14-3-3 homologues. J. Mol. Biol. 268, 619630.
  • White J. G., Southgate E., Thomson J. N. and Brenner S. (1986) The structure of the nervous system of the nematode Caenorhabditis elegans. Philos. Trans. R. Soc. Lond. B Biol. Sci. 314, 1340.
  • Xu J., Kao S. Y., Lee F. J., Song W., Jin L. W. and Yankner B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600606.
  • Zhou W., Hurlbert M. S., Schaack J., Prasad K. N. and Freed C. R. (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 3343.
  • Zhou W., Schaack J., Zawada W. M. and Freed C. R. (2002) Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926, 4250.